EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

EyePoint Pharmaceuticals (Nasdaq: EYPT) granted non-statutory stock options as inducement awards under NASDAQ Listing Rule 5635(c)(4) to seven new employees totaling 31,000 shares.

The options were granted on November 14, 2025, carry an exercise price of $11.58 (closing price that day), have a 10-year term, and vest over four years with 25% vesting at the first anniversary and the remainder monthly over three years, subject to continued service.

WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 31,000 shares of EyePoint common stock to seven new employees. The stock options were granted on November 14, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $11.58 per share, the closing price of EyePoint’s common stock on November 14, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee’s continued service with EyePoint through the applicable vesting dates.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data for the LUGANO trial anticipated in mid-2026 with LUCIA to closely follow. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901.

DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

For EyePoint:

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

What did EyePoint (EYPT) announce on November 17, 2025 about inducement grants?

EyePoint announced non-statutory stock options totaling 31,000 shares granted as inducement awards to seven new employees under Nasdaq Rule 5635(c)(4).

What is the exercise price and grant date for the EyePoint (EYPT) options?

The options were granted on November 14, 2025 with an exercise price of $11.58 per share (closing price that day).

How long is the option term and what is the vesting schedule for EyePoint (EYPT)?

Options have a 10-year term and vest over four years: 25% at the first anniversary, then monthly vesting over the next three years.

How many employees received inducement awards from EyePoint (EYPT) and how many shares were granted?

Seven new employees received inducement option awards totaling 31,000 shares of EyePoint common stock.

Are the EyePoint (EYPT) inducement options contingent on continued employment?

Yes, vesting of the options is subject to each employee's continued service through the applicable vesting dates.

Under which Nasdaq rule were EyePoint's (EYPT) new-hire option grants made?

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material to each employee entering employment.